4.8 Article

An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

Evaluation of an antibody to α4β7 in the control of SIVmac239-nef-stop infection

M. Di Mascio et al.

SCIENCE (2019)

Article Multidisciplinary Sciences

Blocling α4β7 integrin binding to SIV does not improve virologic control

Nami Iwamoto et al.

SCIENCE (2019)

Article Medicine, Research & Experimental

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

Timothy Wyant et al.

Article Medicine, General & Internal

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Medicine, General & Internal

Short-Course Antiretroviral Therapy in Primary HIV Infection

Sarah Fidler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Medicine, General & Internal

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Gastroenterology & Hepatology

Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study

Asit Parikh et al.

INFLAMMATORY BOWEL DISEASES (2012)

Article Medicine, General & Internal

Antiretroviral therapy and management of HIV infection

Paul A. Volberding et al.

LANCET (2010)

Article Multidisciplinary Sciences

The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1

Claudia Cicala et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)